-+ 0.00%
-+ 0.00%
-+ 0.00%

GE Healthcare Announces Phase 2 Results Support Advancement Into Phase 3 For International, Multicenter LUMINA Trial Of Mangaciclanol, With Dose Selection Of 0.1mmol/Kg

Benzinga·11/19/2026 13:06:03
  • Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference
  • Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration
  • Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year
  • GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater)

GE HealthCare (NASDAQ:GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated.